Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Nucleolin–ribosomal DNA (rDNA) G-quadruplex (G4) complex is a regulatory assembly where the multifunctional protein nucleolin binds to G-rich sequences in rDNA that fold into four-stranded G4 structures (Hannan et al., 2013, Nature Reviews Drug Discovery). This interaction is a key regulator of RNA polymerase I (Pol I) transcription, which is responsible for synthesizing the precursor to ribosomal RNA (rRNA) (Ugrinova et al., 2018, Molecules). In cancer cells, nucleolin is often overexpressed and localized to these G4 sites to maintain the high levels of ribosome biogenesis required for rapid proliferation (Drygin et al., 2010, Cancer Research). Small molecules like CX-5461 (Pidnarulex) and CX-3543 (Quarfloxin) target this complex by stabilizing the G4 structures or displacing nucleolin, thereby inhibiting Pol I transcription and inducing nucleolar stress (Quin et al., 2016, Oncotarget). This disruption activates the DNA damage response and p53-dependent or independent apoptotic pathways, making the complex a significant target for anti-cancer therapy (Bywater et al., 2012, Cancer Cell). Beyond rDNA, nucleolin's interaction with G4s in promoter regions of oncogenes like c-MYC further underscores its importance in oncogenic signaling (Gonzalez and Hurley, 2010, Annual Review of Pharmacology and Toxicology). Targeting this specific protein-DNA interface offers a strategy to selectively impair the hyperactivated translational machinery of malignant cells while sparing normal cells to some extent.
Stabilization of G-quadruplex structures and displacement of nucleolin to inhibit RNA polymerase I-mediated transcription and induce nucleolar stress.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nucleolin–ribosomal DNA G-quadruplex complex (NCL–rDNA G4 complex).